Trial Profile

A Randomized, Double Blind, Vehicle-controlled, Multicenter Phase II Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the Treatment of Moderate to Severe Acne Vulgaris in Adults With Photodynamic Therapy (PDT)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2025 According to a Biofrontera AG media release, company announced today successful enrollment of the final patient in this Phase 2b clinical trial evaluating Ameluz (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris. The company also anticipates last-patient-out in Q3 2025.
01 May 2025 Status changed from recruiting to active, no longer recruiting.
21 Mar 2025 According to a Biofrontera AG media release, the company is close to concluding patient recruitment in our phase 2 acne study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com